These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32460142)

  • 61. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 62. Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports.
    Westermeyer J; McCance-Katz EF
    Am J Addict; 2012; 21(5):401-3. PubMed ID: 22882389
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report.
    Christian NJ; Butner JL; Evarts MS; Weimer MB
    J Addict Med; 2023 Jul-Aug 01; 17(4):488-490. PubMed ID: 37579118
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Case of buprenorphine-associated central sleep apnea resolving with dose reduction.
    Tchikrizov V; Richert AC; Bhardwaj SB
    J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
    Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
    J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
    Bridge TP; Fudala PJ; Herbert S; Leiderman DB
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S79-85. PubMed ID: 12738352
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
    Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
    J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 75. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
    Balhara YPS; Singh S; Sarkar S
    Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nonprescription use of buprenorphine tablets among patients at a tertiary care addictive disorder treatment center in India: Observa-tions and implications.
    Balhara YPS; Saha P; Mathew M; Kumar M; Parmar A; Lal R; Sarkar S
    J Opioid Manag; 2023; 19(5):403-411. PubMed ID: 37968974
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence.
    Orman JS; Keating GM
    CNS Drugs; 2009 Oct; 23(10):899-902. PubMed ID: 19739698
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
    Roe M; Wilson CG; Fusco CW; Hulkower S; Stigleman S
    J Fam Pract; 2020 Dec; 69(10):E14-E15. PubMed ID: 33348352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.